Stock Price Quote

MEDICAMEN BIOTECH LTD.

NSE : MEDICAMEQBSE : 531146ISIN CODE : INE646B01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE512.20-10.65 (-2.04 %)
PREV CLOSE ( ) 522.85
OPEN PRICE ( ) 520.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 193
TODAY'S LOW / HIGH ( )504.85 520.00
52 WK LOW / HIGH ( )356.75 630
NSE512.20-12.8 (-2.44 %)
PREV CLOSE( ) 525.00
OPEN PRICE ( ) 524.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 512.20 (15)
VOLUME 15082
TODAY'S LOW / HIGH( ) 502.40 524.95
52 WK LOW / HIGH ( )355.45 630
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1993
Management Info
Rahul Bishnoi - Chairman - Managing Director
Registered Office

Address 1506,Chiranjiv Tower,43, Nehru Place,
New Delhi,
Delhi-110019

Phone 011-47589500-51

Email info@medicamen.com

Website www.medicamen.com

Registrars Details
MUFG Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE

NEWS

04Jan Medicamen Biotech informs about chang
Pursuant to the regulation 30 of the SEBI Listing Regulations, Medicamen..
06Dec Clarification sought from Medicamen B
The Exchange has sought clarification from Medicamen Biotech Ltd on Dece..
11Sep Medicamen Biotech’s Bhiwadi Formulatio
Medicamen Biotech’s General Tablets and Liquid Orals Formulation facilit..
03Sep Medicamen Biotech informs about newspa
Pursuant to Regulation 47 and 30 read with Para A of Schedule III of Sec..
02Sep Medicamen Biotech informs about book c
In terms of Regulation 42 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Sep 24 ANNUAL 24
Net Profit22.7132.99
Gross Profit 32.55 168.89
Operating Profit 68.39282.74
Net Sales 428.441723.86

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  29796.40 (2.39%)
M.Cap ( in Cr)63315.27
Torrent Pharma (BSE)
peergroup  3259.40 (3.10%)
M.Cap ( in Cr)110312.91
Aarti Pharmalabs (BSE)
peergroup  740.55 (8.93%)
M.Cap ( in Cr)6711.31
Astrazeneca Pharma I (BSE)
peergroup  7639.45 (0.60%)
M.Cap ( in Cr)19098.63
Caplin Point Lab (BSE)
peergroup  2216.50 (2.11%)
M.Cap ( in Cr)16847.99

Shareholding Pattern

NON-INSTITUTION 56.04%
PROMOTERS 42.99%
GOVERNMENT 0.06%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
FII 0%

About Medicamen Biotech Ltd.

Medicamen Biotech Ltd. was incorporated in the year 1993. Its today's share price is 512.2. Its current market capitalisation stands at Rs 651.24 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1723.86 Cr and Total Income of Rs.1746.92 Cr. The company's management includes Sanjay Bansal, Suresh Kumar Singh, Ashwani Kumar Sharma, Vimal Kumar Shrawat, Sangeeta Bishnoi, Sumita Dwivedi, Ravi Kumar Bansal, Arun Kumar, Harish Pande, Rahul Bishnoi, Parul Choudhary.

It is listed on the BSE with a BSE Code of 531146 , NSE with an NSE Symbol of MEDICAMEQ and ISIN of INE646B01010. It's Registered office is at 1506,Chiranjiv Tower,43, Nehru PlaceNew Delhi-110019, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashok Sharma & Associates, Rai Qimat & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.